Please select the option that best describes you:
Would you consider anifrolumab in the management of hematologic manifestations in SLE?
Answer from: at Academic Institution
Hematologic manifestations in SLE vary widely from asymptomatic to life-threatening, from cytopenias to severe bleeding to thrombosis to multiorgan failure. Hematologic manifestations can also be compounded by medications, infections, and co-existing conditions. Each of these manifestations is drive...
Sign in or Register to read more
Answer from: at Community Practice
I agree with Dr. @Anna Broder that we are still awaiting more results from the TULIP-1 and TULIP-2 trials on anifrolumab. However, there is data from the phase II clinical trial, the MUSE trial (Casey et al., PMID 30538817), showing improvements in cytopenias (lymphopenia, neutropenia, and thro...